TCTAP C-063 Bioresorbable Vascular Scaffolds in Left Main Coronary Artery Disease
نویسندگان
چکیده
منابع مشابه
[Left main coronary artery disease].
There are many causes of left main coronary artery disease, the first of which is atherosclerosis. Other rarer causes may be observed, such as acute and chronic occlusions, spasm and primary and secondary dissection. The prevalence of stenosis of the left main coronary artery at coronary angiography is about 5%. The risk factors are the same as for coronary artery disease. The symptoms are angi...
متن کاملBioresorbable scaffolds in the treatment of coronary artery disease
Drug-eluting stents have reduced the risk of in-stent restenosis and have broadened the application in percutaneous coronary intervention in coronary artery disease. However, the concept of using a permanent metallic endovascular device to restore the patency of a stenotic artery has inherited pitfalls, namely the presence of a foreign body within the artery causing vascular inflammation, late ...
متن کاملBioresorbable Vascular Scaffolds for Coronary Revascularization.
Contemporary metallic drug-eluting stents are associated with very good 1-year outcomes but an ongoing risk of stent-related adverse events (thrombosis, myocardial infarction, restenosis) after 1 year. The pathogenesis of these very late events is likely related to the permanent presence of the metal stent frame or polymer. Bioresorbable scaffolds have been developed to provide drug delivery an...
متن کاملLeft Main Coronary Artery Disease: traditional risk factors in a study from northwest of Iran
Background & Aims: Significant left main coronary artery disease (LMCAD) is found in 3 to 6 percent of all patients who undergo coronary arteriography. LMCAD usually requires an emergent surgery that has a higher rate of mortality and complications. The risk factors of left main involvement in previous studies are controversial. The aim of this study was to determine the traditional risk factor...
متن کاملBioresorbable Vascular Scaffolds Versus Metallic Stents in Patients With Coronary Artery Disease: ABSORB China Trial.
BACKGROUND The everolimus-eluting bioresorbable vascular scaffold (BVS) is designed to achieve results comparable to metallic drug-eluting stents at 1 year, with improved long-term outcomes. Whether the 1-year clinical and angiographic results of BVS are noninferior to current-generation drug-eluting stents has not been established. OBJECTIVES This study sought to evaluate the angiographic ef...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of the American College of Cardiology
سال: 2018
ISSN: 0735-1097
DOI: 10.1016/j.jacc.2018.03.260